Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | HO4S.H4N |
| Molecular Weight | 115.109 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[NH4+].OS([O-])(=O)=O
InChI
InChIKey=BIGPRXCJEDHCLP-UHFFFAOYSA-N
InChI=1S/H3N.H2O4S/c;1-5(2,3)4/h1H3;(H2,1,2,3,4)
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H3N |
| Molecular Weight | 17.0305 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
SULFATE (as sodium sulfate, potassium sulfate, and magnesium sulfate) is a component of SUPREP Bowel Prep Kit. It is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. Sulfate salts provide sulfate anions, which are poorly absorbed. The osmotic effect of unabsorbed sulfate anions and the associated cations causes water to be retained within the gastrointestinal tract. SUPREP Bowel Prep Kit, when ingested with a large volume of water, produces copious watery diarrhea.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. | 2014-04 |
|
| Evaluation of formocresol versus ferric sulphate primary molar pulpotomy: a systematic review and meta-analysis. | 2007-10 |
|
| Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. | 2007-07-18 |
|
| Heparan sulphate proteoglycans fine-tune mammalian physiology. | 2007-04-26 |
|
| Overcoming chondroitin sulphate proteoglycan inhibition of axon growth in the injured brain: lessons from chondroitinase ABC. | 2007 |
|
| [Therapy of osteoarthritis crystalline glucosamine sulphate/a review of the clinical effcacy]. | 2007 |
|
| Chondroitin sulphate: antioxidant properties and beneficial effects. | 2006-12 |
|
| Dietary acidification enhances phosphorus digestibility but decreases H+/K+-ATPase expression in rainbow trout. | 2006-10 |
|
| The role of heparan sulphate in inflammation. | 2006-09 |
|
| Interferon and heparan sulphate. | 2006-06 |
|
| Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. | 2006-06 |
|
| Heparan sulphate requirement in platelet-derived growth factor B-mediated pericyte recruitment. | 2006-06 |
|
| The role of heparan sulphate proteoglycans in angiogenesis. | 2006-06 |
|
| Insights into the role of heparan sulphate in fibroblast growth factor signalling. | 2006-06 |
|
| Multiprotein signalling complexes: regional assembly on heparan sulphate. | 2006-06 |
|
| Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. | 2006-06 |
|
| Heparan sulphate proteoglycans and viral vectors : ally or foe? | 2006-02 |
|
| [Magnesium sulphate for the management of preeclampsia]. | 2006-01 |
|
| Heparan sulphate proteoglycans: the sweet side of development. | 2005-07 |
|
| A review of the role for magnesium sulphate in preterm labour. | 2005-03 |
|
| Evidence and practice: the magnesium sulphate story. | 2005-02 |
|
| A meta-analysis on intravenous magnesium sulphate for treating acute asthma. | 2005-01 |
|
| Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. | 2005 |
|
| Epidemiology of 377 patients with chemical burns in Guangdong province. | 2004-09 |
|
| Characterization of the Herpesvirus saimiri Orf51 protein. | 2004-08-15 |
|
| Molecular recognition by LARGE is essential for expression of functional dystroglycan. | 2004-06-25 |
|
| [The extracellular matrix of the central nervous system: chondroitin sulphate type proteoglycans and neural repair]. | 2004-05-21 |
|
| The SLC13 gene family of sodium sulphate/carboxylate cotransporters. | 2004-02 |
|
| Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? | 2004-01 |
|
| Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. | 2003-10 |
|
| Dermatan sulphate as an antithrombotic drug. | 2003-09-19 |
|
| Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. | 2003-08 |
|
| Magnesium sulphate versus phenytoin for eclampsia. | 2003 |
|
| Magnesium sulphate versus diazepam for eclampsia. | 2003 |
|
| Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. | 2003 |
|
| Structure-activity relationship of heparan sulphate. | 1997-11 |
|
| Heparan sulphate proteoglycan and wound healing in skin. | 1997-11 |
|
| Heparan sulphate. | 1997-05 |
|
| Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. | 1996-09 |
|
| The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. | 1996-06 |
|
| The role of stromal cell heparan sulphate in regulating haemopoiesis. | 1996-05 |
|
| Two selectins converge on sulphate. Leukocyte adhesion. | 1996-03-01 |
|
| Renal and small intestinal sodium-dependent symporters of phosphate and sulphate. | 1994-11 |
|
| Dextran sulphate induces a PKC and actin independent internalisation of CD4. | 1994-09 |
|
| Keratan sulphate--a 'reserve' polysaccharide? | 1994-04 |
|
| Death by tanning--a case of fatal basic chromium sulphate poisoning. | 1994 |
|
| Heparan sulphate in the binding and activation of basic fibroblast growth factor. | 1992-12 |
|
| Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. | 1992-04 |
|
| Sodium dodecyl sulphate electrophoresis of urinary proteins. | 1991-09-13 |
|
| Management of autonomic dysfunction in severe tetanus: the use of magnesium sulphate and clonidine. | 1990 |
Patents
Sample Use Guides
Split-Dose (2-Day) Regimen:
The evening before colonoscopy: dilute one bottle with water to a total volume of 16 oz. (up to the fill line) and drink the entire amount. Drink 32 ounces of water over the next hour.
Next morning: repeat both steps using the second bottle. Complete preparation at least 2 hours before colonoscopy or as directed by a physician.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:08:56 GMT 2025
by
admin
on
Mon Mar 31 21:08:56 GMT 2025
|
| Record UNII |
6218R7MBZB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24655
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
6218R7MBZB
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
7803-63-6
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
232-265-5
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
DTXSID9051244
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
m1767
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
AMMONIUM BISULFATE
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY | |||
|
C034007
Created by
admin on Mon Mar 31 21:08:56 GMT 2025 , Edited by admin on Mon Mar 31 21:08:56 GMT 2025
|
PRIMARY |